
Multiple Myeloma Research Foundation News
203 FOLLOWERS
A pioneer in precision medicine, the Multiple Myeloma Research Foundation (MMRF) seeks to find a cure for all multiple myeloma patients by relentlessly pursuing innovations that accelerate the development of precision treatments for cancer. Find the latest multiple myeloma news on drug development, clinical trials or myeloma research at The MMRF.
Multiple Myeloma Research Foundation News
1M ago
In September 2024, Sarclisa (isatuximab) became the first drug to be approved by the FDA for use with Velcade, Revlimid, and dexamethasone (Isa-VRd) for adult patients who are newly diagnosed with multiple myeloma but unable to receive high-dose chemotherapy and a stem cell transplant commonly used in myeloma treatment. With this new approval, patients with […]
The post Sarclisa (isatuximab): A New Option for Patients With Newly Diagnosed Myeloma Not Eligible for Transplant appeared first on MMRF ..read more
Multiple Myeloma Research Foundation News
1M ago
The MMRF aims to incorporate a variety of new bispecific antibodies, cell therapies, checkpoint inhibitors and novel small molecules into the Horizon study. Download the PDF
The post With Plethora Of New Myeloma Treatments, MMRF Study Aims To Better Guide Use appeared first on MMRF ..read more
Multiple Myeloma Research Foundation News
1M ago
This article presents a Q&A with MMRF Patient Navigation Center nurses Grace Allison and Brittany Hartmann on key takeaways from the 2024 annual meetings of the National Comprehensive Cancer Network (NCCN) and the Journal of the Advanced Practitioner in Oncology (JADPRO) on recent multiple myeloma treatment advances. What have we learned about the side effects […]
The post MMRF Patient Navigator Q&A: Nursing Insights From the NCCN and JADPRO Annual Meetings appeared first on MMRF ..read more
Multiple Myeloma Research Foundation News
1M ago
The Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced investments in Luminary Therapeutics, a company using advanced receptor design to improve the depth and durability of patient responses to cell therapy; KAHR, a clinical stage company developing immune-recruiting therapies to address immune escape by tumors; and Telo Therapeutics, a biotechnology company developing second generation inhibitors of nuclear transport against a clinically validated target for multiple myeloma.
The post Indapta Therapeutics Secures ..read more
Multiple Myeloma Research Foundation News
2M ago
Norwalk, Conn., December 11, 2024 – The Multiple Myeloma Research Foundation® (MMRF®) and Family Reach, a national nonprofit providing financial support to families facing cancer, announced today a partnership to support more equitable access to clinical trials for multiple myeloma patients. This is the continuation of an action plan the MMRF developed to improve diversity and representation […]
The post Multiple Myeloma Research Foundation Partners with Family Reach to Deliver Critical Financial Support to Multiple Myeloma Patients and their Families appeared first on MMRF ..read more
Multiple Myeloma Research Foundation News
2M ago
Welcome to our final recap of the latest research on myeloma treatments presented at the American Society of Hematology (ASH) Annual Meeting in San Diego. Highlights from the final day included: Promising data on Darzalex significantly delaying disease progression in high-risk smoldering multiple myeloma New updates on Sarclisa-based quadruplet regimens for newly diagnosed multiple myeloma […]
The post MMRF ASH 2024 Blog: Day 3 appeared first on MMRF ..read more
Multiple Myeloma Research Foundation News
2M ago
Welcome to the second day of our recap of the latest findings on myeloma treatments reported at the American Society of Hematology (ASH) meeting in San Diego. Highlights from today included: Promising data on the use of the bispecific antibody Tecvayli (teclistimab) for newly diagnosed patients or early relapse Insights on Etentamig (formerly ABBV-383), a […]
The post MMRF ASH 2024 Blog: Day 2 appeared first on MMRF ..read more
Multiple Myeloma Research Foundation News
2M ago
Welcome to our 2024 recap of the latest research on myeloma treatments reported at the American Society of Hematology (ASH) meeting that kicked off Saturday in San Diego. Highlights from today included: Data to support stopping maintenance therapy after a sustained deep remission New insights into how to more accurately identify patients with high-risk disease […]
The post MMRF ASH 2024 Blog: Day 1 appeared first on MMRF ..read more
Multiple Myeloma Research Foundation News
2M ago
Data from the MMRF CoMMpassSM and Immune Atlas programs are featured in 36 abstracts, continuing to transform the understanding of myeloma biology and drive impactful research Norwalk, Conn., December 6, 2024 – The Multiple Myeloma Research Foundation (MMRF®) today announced upcoming poster and oral presentations at the 66th American Society of Hematology (ASH) Annual Meeting and […]
The post Multiple Myeloma Research Foundation (MMRF) Programs Power New Insights into High-Risk Multiple Myeloma at the 66th American Society of Hematology Annual Meeting appeared first on MMRF ..read more
Multiple Myeloma Research Foundation News
2M ago
The Horizon Clinical Trials Program uses an adaptive platform designed to test multiple therapies simultaneously to determine the best combination, sequence, and duration of therapy to improve patient outcomes Norwalk, Conn., December 4, 2024 – The Multiple Myeloma Research Foundation (MMRF®) announced today that the first patient had been enrolled in the first arm of its […]
The post The Multiple Myeloma Research Foundation (MMRF) Announces the First Patient Enrolled in its Horizon Clinical Trials Program to Accelerate the Identification of Optimal Treatment Strategies for Multiple Myelo ..read more